Consoli Marcella Lobato D, da Silva Raphael Steinberg, Nicoli Jacques Robert, Bruña-Romero Oscar, da Silva Rodrigo Gomes, de Vasconcelos Generoso Simone, Correia Maria Isabel T D
Surgery Postgraduate Program, Medical School, Universidade Federal de Minas Gerais, Minas Gerais, Brazil.
Department of Microbiology, Biology Science Institute, Universidade Federal de Minas Gerais, Minas Gerais, Brazil.
JPEN J Parenter Enteral Nutr. 2016 Nov;40(8):1114-1121. doi: 10.1177/0148607115584387. Epub 2015 Apr 27.
When intestinal microbiota is imbalanced, a patient becomes more vulnerable to infectious complications; intervention with beneficial probiotics may help lower risk for infection. The aim of this study was to measure levels of inflammatory cytokine messenger RNA (mRNA) in surgical samples of intestinal mucosal tissues from patients who were given the probiotic Saccharomyces boulardii before undergoing colon surgery.
Thirty-three patients undergoing colon resection were randomly assigned to receive at least 7-day preoperative probiotic treatment (n = 15) or conventional (n = 18) treatment. Probiotic treatment consisted of oral lyophilized S boulardii Cytokine mRNA levels (interleukin [IL]-10, IL-1β, IL-23A, tumor necrosis factor [TNF]-α, IL-12B, interferon-γ [INF-γ], and IL-17A) were measured in samples obtained during the operation. Postoperative infections were also assessed.
Patients who received probiotics had significantly lower mucosal IL-1β, IL-10, and IL-23A mRNA levels than the control group (P = .001, P = .04, and P = .03, respectively). However, mRNA expression of other cytokines did not differ between the 2 groups (P > .05). The incidence of postoperative infectious complications was 13.3% and 38.8% in probiotic and control groups, respectively (P > .05). There was no perioperative mortality in either group. The mean total length of hospital stay was similar between the groups (P > .05).
Probiotic treatment with S boulardii downregulates both pro- and anti-inflammatory cytokines in the intestinal colonic mucosa with no statistical impact on postoperative infection rates.
当肠道微生物群失衡时，患者更容易发生感染性并发症；使用有益的益生菌进行干预可能有助于降低感染风险。本研究的目的是测量在接受结肠手术前服用益生菌布拉酵母菌的患者的肠黏膜组织手术样本中炎性细胞因子信使核糖核酸（mRNA）的水平。
33例行结肠切除术的患者被随机分配接受至少7天的术前益生菌治疗（n = 15）或传统治疗（n = 18）。益生菌治疗包括口服冻干布拉酵母菌。在手术过程中获取的样本中测量细胞因子mRNA水平（白细胞介素[IL]-10、IL-1β、IL-23A、肿瘤坏死因子[TNF]-α、IL-12B、干扰素-γ[INF-γ]和IL-17A）。还评估了术后感染情况。
接受益生菌治疗的患者黏膜IL-1β、IL-10和IL-23A mRNA水平显著低于对照组（分别为P = .001、P = .04和P = .03）。然而，两组间其他细胞因子的mRNA表达无差异（P > .05）。益生菌组和对照组术后感染性并发症的发生率分别为13.3%和38.8%（P > .05）。两组均无围手术期死亡。两组的平均住院总时长相似（P > .05）。
布拉酵母菌益生菌治疗可下调结肠黏膜中促炎和抗炎细胞因子，对术后感染率无统计学影响。
